Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Biocartis, Synthego, Sophia Genetics

Biocartis Idylla ctEGFR Mutation Assay

Biocartis has globally launched its Idylla ctEGFR Mutation Assay. The firm noted that the research-use-only tool is the liquid biopsy version of its solid biopsy Idylla EGFR Mutation Test. Running on the Idylla platform, the assay allows users to detect 49 EGFR mutations directly from 2 ml of blood plasma and provides resutls within 160 minutes, Biocartis said.


Synthego High-Throughput Induced Pluripotent Stem Cell Genome Engineering Service

Synthego has launched a genome engineering service for induced pluripotent stem (iPS) cells. The new offering expands on Synthego's automated cell editing technology to achieve high editing efficiency of iPS cells at an industrial scale. Synthego said its cell-editing platform makes editing, cloning, and maintaining high pluripotency in clinically relevant iPS cells easier, with editing rates as high as 90 percent prior to cloning and 100 percent in clones. The new offering of iPS cells includes modifications by gene knockout, single-nucleotide variation, protein tagging, and other knock-ins.


Sophia Genetics Whole Exome Solution

Sophia Genetics has released a new version of Sophia Whole Exome Solution, which the company said reduces turnaround time for analysis of whole-exome sequences. The updated Sophia WES now features detection of copy-number variations at a resolution of two to five exons without the need for a reference sample. The product also supports analysis of variants in familial trios to filter variants based on different inheritance modes.


For more new products and services, please visit the New Products page on our website.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more